NeoGenomics (NEO) Given a $19.00 Price Target by CIBC Analysts

NeoGenomics (NASDAQ:NEO) has been assigned a $19.00 price target by equities research analysts at CIBC in a report issued on Wednesday, January 3rd. The firm presently has a “neutral” rating on the medical research company’s stock. CIBC’s price target would indicate a potential upside of 123.27% from the company’s current price.

Several other equities analysts also recently commented on NEO. Janney Montgomery Scott reiterated a “buy” rating on shares of NeoGenomics in a report on Thursday, October 26th. Zacks Investment Research downgraded NeoGenomics from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. BidaskClub downgraded shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. Finally, BTIG Research downgraded shares of NeoGenomics from a “buy” rating to a “neutral” rating in a research note on Monday, September 11th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $15.83.

Shares of NeoGenomics (NEO) traded up $0.03 on Wednesday, reaching $8.51. 442,774 shares of the company were exchanged, compared to its average volume of 248,659. The company has a quick ratio of 1.99, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. NeoGenomics has a 12-month low of $7.12 and a 12-month high of $11.63. The company has a market cap of $689.31, a price-to-earnings ratio of -24.31, a PEG ratio of 3.52 and a beta of 0.84.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.01 EPS for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $63.05 million during the quarter, compared to analyst estimates of $63.11 million. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.97%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 earnings per share. research analysts anticipate that NeoGenomics will post 0.04 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new position in shares of NeoGenomics during the 3rd quarter valued at about $369,000. California Public Employees Retirement System lifted its stake in NeoGenomics by 12.7% in the 3rd quarter. California Public Employees Retirement System now owns 101,663 shares of the medical research company’s stock valued at $1,132,000 after acquiring an additional 11,463 shares in the last quarter. Granahan Investment Management Inc. MA lifted its stake in NeoGenomics by 5.3% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 1,065,082 shares of the medical research company’s stock valued at $11,854,000 after acquiring an additional 53,958 shares in the last quarter. Janus Henderson Group PLC lifted its stake in NeoGenomics by 50.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,464,655 shares of the medical research company’s stock valued at $38,562,000 after acquiring an additional 1,159,888 shares in the last quarter. Finally, PEAK6 Investments L.P. bought a new stake in NeoGenomics in the 3rd quarter valued at approximately $592,000. Hedge funds and other institutional investors own 83.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/neogenomics-neo-given-a-19-00-price-target-at-cibc.html.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Analyst Recommendations for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply